Prediction and prevention of schizophrenia: What has been achieved and where to go next?

World Psychiatry

Volumn 10, Issue 3, 2011, Pages 165-174

  Klosterkötter, Joachim ^a   Schultze Lutter, Frauke ^b   Bechdolf, Andreas ^a,c   Ruhrmann, Stephan ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Basic symptoms; Differentiated prevention; Early course; High risk symptoms; Risk factors; Risk staging; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; OLANZAPINE; RISPERIDONE;

COGNITIVE DEFECT; COGNITIVE THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FOLLOW UP; HUMAN; MENTAL DISEASE; MENTAL HEALTH; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA;

EID: 80155145244     PISSN: 17238617     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2051-5545.2011.tb00044.x     Document Type: Review

References (68)

1. Bundesministeriums für Gesundheit. Maßnahmen des Bundesministeriums für Gesundheit zur Umsetzung nationaler Gesundheitsziele. Berlin: Bundesministerium für Gesundheit, 2007.
2. Commonwealth Department of Health and Aged Care. Promotion, prevention and early intervention for mental health - a monograph. Canberra: Commonwealth Department of Health and Aged Care, 2000.
3. European Commission. Green Paper - Improving mental health of the population: towards a strategy on mental health for the European Union. Brussels: European Commission, 2005.
4. World Health Organization. Prevention of mental disorders: effective interventions and policy options. Geneva: World Health Organization, 2004.
5. Häfner H, an der Heiden W. Course and outcome. In: Mueser KT, Jeste DV (eds). Clinical handbook of schizophrenia. New York: Guilford, 2008:100-13.
6. Harrison G, Hopper K, Craig T et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001;178:506-17. (Pubitemid 32531743)
7. Clouth J. Costs of early retirement - the case of schizophrenia. Psychiatr Prax 2004;31(Suppl. 2):S238-45. (Pubitemid 40007470)
8. Rössler W, Salize HJ, van Os J et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005;15:399-409. (Pubitemid 40943544)
9. Samnaliev M, Clark RE. The economics of schizophrenia. In: Mueser KT, Jeste DV (eds). Clinical handbook of schizophrenia. New York: Guilford, 2008:507-15.
10. Gutiérrez-Maldonado J, Caqueo-Urízar A, Kavanagh D. Burden of care and general health in families of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2005;40:899-904. (Pubitemid 41662419)
11. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression and neuropathology on the matter of their convergence. Mol Psychiatry 2005;10(Suppl. 3):40-68. (Pubitemid 40139588)
12. Seidman LJ, Giuliano AJ, Meyer EC et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 2010;67:578-88.
13. van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635-45.
14. Häfner H, Maurer K, Löffler W et al. The ABC Schizophrenia Study: a preliminary overview of the results. Soc Psychiatry Psychiatr Epidemiol 1998;33:380-6. (Pubitemid 28377066)
15. Schultze-Lutter F, Ruhrmann S, Berning J et al. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 2010;36:182-91.
16. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 2003;36(Suppl. 3):S162-7. (Pubitemid 38085132)
17. Marshall M, Lewis S, Lockwood A et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005;62:975-83. (Pubitemid 41248376)
18. Klosterkötter J, Hellmich M, Steinmeyer EM et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001;58:158-64. (Pubitemid 32142753)
19. Huber G, Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recent Prog Med 1989;80:646-52.
20. Gross G. The 'basic' symptoms of schizophrenia. Br J Psychiatry 1989;7:21-5. (Pubitemid 19270843)
21. Gross G, Huber G, Klosterkötter J et al. Bonner Skala für die Beurteilung von Basissymptomen (BSABS; Bonn Scale for the Assessment of Basic Symptoms). Berlin: Springer, 1987.
22. Schultze-Lutter F, Addington J, Ruhrmann S et al. Schizophrenia Proneness Instrument, Adult version (SPI-A). Rome: Fioriti, 2007.
23. Schultze-Lutter F, Koch E. Schizophrenia Proneness Instrument, Child & Youth version (SPI-CY). Rome: Fioriti, 2010.
24. Schultze-Lutter F, Steinmeyer EM, Ruhrmann S et al. The dimensional structure of self-reported 'prodromal' disturbances in schizophrenia. Clin Neuropsychiatry 2008;5:140-50.
25. Schultze-Lutter F, Ruhrmann S, Klosterkötter J. Can schizophrenia be predicted phenomenologically? In: Johannessen JO, Martindale B, Cullberg J (eds). Evolving psychosis. Different stages, different treatments. London: Routledge, 2006:104-23.
26. Schultze-Lutter F, Klosterkötter J, Picker H et al. Predicting first-episode psychosis by basic symptom criteria. Clin Neuropsychiatry 2007;4:11-22. (Pubitemid 47072411)
27. Yung AR, Phillips LJ, McGorry PD et al. Prediction of psychosis. Br J Psychiatry 1998;172(Suppl. 33):14-20.
28. Phillips LJ, Yung AR, McGorry PD. Identification of young people at risk of psychosis: validation of personal assessment and crisis evaluation clinic intake criteria. Aust N Z J Psychiatry 2000;34:S164-9.
29. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry 2005;39:964-71. (Pubitemid 43904432)
30. Miller TJ, McGlashan TH, Rosen JL et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002;159:863-5. (Pubitemid 34465065)
31. McGlashan T, Walsh B, Woods S. The psychosis-risk syndrome. Handbook for diagnosis and follow-up. New York: Oxford University Press, 2010.
32. Cornblatt B. The New York High-Risk Project to the Hillside Recognition and Prevention (RAP) Program. Am J Med Genet 2002; 114:956-66. (Pubitemid 35379240)
33. Riecher-Rössler A, Geschwandtner U, Aston J et al. The Basel early-detection-of-psychosis (FEPSY)-study - design and preliminary results. Acta Psychiatr Scand 2007;115:114-25. (Pubitemid 46114872)
34. Yung AR, Stanford C, Cosgrave E et al. Testing the ultra high risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res 2006;84:57-66. (Pubitemid 44255719)
35. Yung AR, Nelson B, Stanford C et al. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res 2008;105:10-7.
36. Woods SW, Addington J, Cadenhead KS et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull 2009;35:894-908.
37. Lencz T, Smith CW, Auther A et al. The assessment of "prodromal schizophrenia": unresolved issues and future directions. Schizophr Bull 2003;29:717-28. (Pubitemid 38181952)
38. Mason O, Startup M, Halpin S et al. Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states'. Schizophr Res 2004;71:227-37. (Pubitemid 39330501)
39. Yung AR, Phillips LJ, Yuen HP et al. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004;67:131-42. (Pubitemid 38251443)
40. Cannon TD, Cadenhead K, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008;65:28-37.
41. Ruhrmann S, Schultze-Lutter F, Salokangas RK et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European Prediction of Psychosis Study (EPOS). Arch Gen Psychiatry 2010;67:241-51.
42. Kirkbride JB, Fearon P, Morgan C et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AESOP study. Arch Gen Psychiatry 2006;63:250-8. (Pubitemid 43345348)
43. Mrazek PJ, Haggerty RJ (eds). Reducing risks for mental disorders: frontiers for preventive intervention research. Washington: National Academy Press, 1994.
44. McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002;59:921-8
45. Phillips LJ, McGorry PD, Yuen HP et al. Medium-term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 2007;96:25-33. (Pubitemid 47494628)
46. Morrison AP, French P, Walford L et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Br J Psychiatry 2004;185:291-7. (Pubitemid 39331330)
47. Morrison AP, French P, Parker S et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 2007;33:682-7. (Pubitemid 47343709)
48. McGlashan TH, Zipursky RB, Perkins D et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res 2003;61:7-18. (Pubitemid 36332135)
49. Häfner H, Maurer K, Ruhrmann S et al. Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci 2004;254:117-28. (Pubitemid 39304479)
50. Bechdolf A, Wagner M, Harrigan S et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry (in press).
51. Ruhrmann S, Schultze-Lutter F, Maier W et al. Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry 2005;20:1-6. (Pubitemid 40092385)
52. Bechdolf A, Müller H, Stützer H et al. Rationale and baseline characteristics of PREVENT: a second generation intervention trial in subjects at-risk (prodromal) of developing first episode psychosis evaluating cognitive behaviour therapy, aripiprazole and placebo for the prevention of psychosis. Schizophr Bull (in press).
53. Woods SW, Tully EM, Walsh BC et al. Aripiprazole in the treatment of the psychosis prodrome. An open-label pilot study. Br J Psychiatry 2007;191(Suppl. 51):96-101.
54. Cornblatt BA, Lencz T, Smith CW et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007;68:546-57. (Pubitemid 46663037)
55. Hampel H, Frank R, Broich K et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560-74.
56. Borgwardt SJ, McGuire PK, Aston J et al. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br J Psychiatry 2007;191(Suppl. 51):69-75.
57. Brockhaus-Dumke A, Schultze-Lutter F, Mueller R et al. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiatry 2008;64:376-84.
58. Pantelis C, Velakoulis D, Wood SJ et al. Neuroimaging and emerging psychotic disorders: the Melbourne ultra-high risk studies. Int Rev Psychiatry 2007;19:371-81.
59. Pukrop R, Schultze-Lutter F, Ruhrmann S et al. Neurocognitive functioning in subjects at risk for a first episode of psychosis compared with first- and multiple-episode schizophrenia. J Clin Exp Neuropsychiatry 2006;28:1388-407. (Pubitemid 44578245)
60. Witthaus H, Kaufmann C, Bohner G et al. Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Res 2008;173:163-9.
61. The European Network of Schizophrenia Networks for the Study of Gene-Environment Interactions (EU-GEI). Schizophrenia aetiology: do gene-environment interactions hold the key? Schizophr Res 2008;102:21-6.
62. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Probably at-risk, but certainly ill - Advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 2010;120:23-37.
63. Lieberman JA. Neuroprotection: a new strategy in the treatment of schizophrenia. Neurobiological basis of neurodegeneration and neuroprotection. CNS Spectr 2007;12(Suppl. 18):4-6.
64. Berger G, Dell'Olio M, Amminger P et al. Neuroprotection in emerging psychotic disorders. Early Interv Psychiatry 2007;1:114-27.
65. Amminger GP, Schäfer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67:146-54.
66. Woods SW, Walsh B, Pearlson GD et al. Glycine treatment of prodromal symptoms. Schizophr Res 2006;86:S7-S17.
67. Berger G, Wood SJ, Dell'Olio M et al. Neuroprotective effects of low dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Schizophr Res 2008;102:39-40.
68. Nelson B, McGorry P, Yung A et al. The NEURAPRO (North America, Europe, Australia Prodrome) Study: a multicenter RCT of treatment strategies for symptomatic patients at ultra-high risk for progression to schizophrenia and related disorders. Design and study plan. Schizophr Res 2008;102(Suppl. 2):295.